✨ Free AI Report
Eton Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Eton Pharmaceuticals, Inc.
Company Research

Eton Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Eton Pharmaceuticals, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Eton is a lean, high-growth rare-disease specialist with validated products, strong commercial momentum, and strategic pipeline expansion positioned to capture premium pricing in orphan indications. Eton demonstrates exceptional execution with near-doubling revenue growth, successful portfolio expansion through launches and acquisitions, and FDA validation (Fast Track designation). Small employee base.

What is Eton Pharmaceuticals, Inc.'s industry? Eton Pharmaceuticals, Inc. (etonpharma.com) operates in Pharmaceuticals. AskCyborg classifies Eton Pharmaceuticals, Inc. under Pharmaceuticals in its company registry.

Eton Pharmaceuticals is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company has over 11 commercial rare disease products including INCRELEX, ALKINDI SPRINKLE, D...

8/ 10Strong

Cyborg Score thesis

Eton is a lean, high-growth rare-disease specialist with validated products, strong commercial momentum, and strategic pipeline...

Read the full analyst-debate transcript →
Industry Pharmaceuticals
4 named competitors
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Eton Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Eton Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Eton Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Eton Pharmaceuticals, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Eton Pharmaceuticals, Inc. Overview

Pro stress-test →

Eton Pharmaceuticals is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company has over 11 commercial rare disease products including INCRELEX, ALKINDI SPRINKLE, DESMODA, GALZIN, HEMANGEOL, and others, addressing endocrine, metabolic, and orphan disease indications with high unmet medical needs.

Strategic Profile

Pro stress-test →

Eton reported 99% year-over-year revenue growth in Q2 2026, reflecting strength in its rare disease portfolio.

Competitive Landscape

Pro stress-test →

Eton competes in the rare disease therapeutics market against specialized pharma companies focused on ultra-orphan indications. Key competitors include Nymox Pharmaceutical and other specialty companies targeting endocrine, metabolic, and orphan disease niches. Eton's differentiation rests on its growing commercial-stage portfolio, efficient go-to-market approach, and FDA validation for rare disease products.

Industry Context

Eton Pharmaceuticals, Inc. operates in Pharmaceuticals.

Key facts

Founded: 2017 · Headquarters: Deer Park, IL, United States · Employees: 44 · Revenue: $145M+ (FY2026 guidance as of August 2026); TTM revenue $86.9M as of March 31, 2026 · Market cap: $1.15B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Eton Pharmaceuticals, Inc..

  • Q2 2026 revenue surged 99% year-over-year, driven by HEMANGEOL relaunch and portfolio expansion. For a ~$1.15B market-cap company, this growth trajectory signals strong product-market fit and market acceptance for rare disease therapies, supporting premium valuations.
  • Four late-stage pipeline candidates including Amglidia, ET-700, ET-800, and ZENEO hydrocortisone autoinjectors address high-incidence rare endocrine and metabolic indications, providing multi-year growth optionality and potential revenue expansion.

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Ultragenyx PharmaceuticalBiopharmaceutical company developing treatments for rare and ultra-rare genetic diseases→Cara TherapeuticsSpecialty pharmaceutical company focused on rare disease treatments including metabolic and endocrine disorders→Aeglea BioTherapeuticsClinical and commercial-stage biopharmaceutical company developing therapies for rare metabolic and rare genetic diseases→Eidos TherapeuticsSpecialty pharma company focused on development of therapies for rare genetic diseases with high unmet medical need→

Compare Eton Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Eton Pharmaceuticals, Inc. operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Eton Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Eton Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Eton Pharmaceuticals, Inc. do this quarter?”
“Is Eton Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Eton Pharmaceuticals, Inc. do?+
Eton Pharmaceuticals is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company has over 11 commercial rare disease products including INCRELEX, ALKINDI SPRINKLE, D...
What is Eton Pharmaceuticals, Inc.'s Cyborg Score?+
Eton Pharmaceuticals, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Eton Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Ultragenyx Pharmaceutical, Cara Therapeutics, Aeglea BioTherapeutics, Eidos Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Eton Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Eton Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Eton Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Novartis AG7Recordati Industria Chimica e Farmaceutica SpA6CSPC Innovation Pharmaceutical Co., Ltd.